Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Myelodysplastic Syndromes 5Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Carcinoma, Squamous Cell 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Head and Neck Neoplasms 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Splenomegaly 1Solid Tumor 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Malignant Neoplasmas 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Esophageal Squamous Cell Carcinoma 1Epidermolysis Bullosa Dystrophica 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × ON 01910 × Clear all
NCT04263090 2024-05-09

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
25 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡